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Proton Pump Inhibitors May Not Be the
First Line of Treatment for GERD
in Infants
T o the Editor: We applaud Krishnan et al (1) for the ESP-GHAN-NASPGHAN guidelines on ‘‘The evaluation and
treatment of gastrointestinal and nutritional complications in chil-
dren with Esophageal atresia /Tracheoesophageal fistula.’’
We agree on the recommendation of gastroesophageal
reflux being treated with acid suppressants from the neonatal
age, though the evidence is not strong. We wish to bring to attention
some special considerations when prescribing proton pump inhibi-
tor (PPI) in the first 12 months of age and more so for the first
6 months.
A strong case exists for the cautious use of PPIs in infants,
more so in infants less than 6 months of age. The pharmacokinetics
(pK) of PPIs in infants differs compared with older children and
adults. Springer et al (2) showed that for the same dose of
lansoprazole, infants less than 10 weeks of age had 5 times higher
plasma total exposure and area under the curve (AUC) of lanso-
prazole compared with infants older than 10 weeks. This extreme
variable plasma level of lansoprazole was also supported by Tran
et al’s (3) study; 2 infants, 18 days and 3.2 months old on
lansoprazole 17 mg/m2 per day, had the longest half-life (t1/2)
and the highest AUC values and the lowest plasma clearance
(CL/F) values. Another study by Anderson et al (4) reported the
pK of omeprazole in 0 to 24-month-old children given a single dose
of omeprazole 1 or 1.5 mg/kg showed increased exposure of
omeprazole for infants less than 5 months, compared with children
5 to 24 months who had consistent levels. Omari et al (5) showed
that in children 1 to 24 months given esomeprazole (0.25 and 1 mg/
kg), children under 12 months had higher AUC and maximum
plasma concentration at steady state (CSSmax) compared with
children older than 12 months. The authors commented that
the maturation of the enzymes required for metabolism of PPIs
(CYP2C19 and CYP3A4) is variable and the metabolism of
esomeprazole may differ early versus late infancy. Pharmacoki-
netics also suggested that immaturity of renal clearance in early
infancy may prolong the t1/2 of drugs leading to higher PPI blood
levels (4,5). Clearance of pantoprazole with increasing age, from
1 month through 6 years, was observed and there were no slow
metabolizers within the infants in this group (6). These studies
clearly demonstrate that infancy is a critical age and PPIs should
be used with caution especially during the first 6 months of age.
Additionally, no pre-made liquid preparation is available for
many PPIs that can be easily administered, a risk for accurate
dosing.
Further Krishnan et al (1) warn about the long-term adverse
effects on the use of PPIs including change in microbiota, C.
difficile colitis, acute gastroenteritis, community-acquired pneu-
monia, bone fractures, dementia, hypomagnesemia, and B12
deficiency. Importantly, infants less than 3 months of age are at
increased risk for sequelae from infection with an immature
immune system (7).
Because PPIs are effective treatment for severe GERD in
children (8), PPIs are the drug of choice for GERD in EA-TEF
children. In infants less than 12 months of age, particularly in the
first 6 months, the practitioner should have a clear indication to use
PPI and be cautious when prescribing PPI.
Thirumazhisai S. Gunasekaran, Samir Kakodkar,
and James H. Berman
Advocate Children’s Hospital, Loyola Medical Cneter,
University of Illinois,
Chicago, IL
REFERENCES
1. Krishnan U, Mousa H, Dall’Oglio L, et al. ESPGHAN-NASPGHAN
guidelines for the evaluation and treatment of gastrointestinal and nutri-
tional complications in children with esophageal atresia/tracheoesopha-
geal fistula. J Pediatr Gastroenterol Nutr 2016;63:550–66.
2. Springer M, Zang W, Atkinson S, et al. Pharmacokinetic and pharma-
codynamic profiles and symptom relief in infants with clinically evident
GERD treated with lansoprazole. Pediatric Drugs 2008;10:155–263.
3. Tran A, Rey E, Pons G, et al. Pharmacokinetic-pharmacodynamic study
of oral lansoprazole in children. Clin Pharmacol Ther 2002;71:359–67.
4. Anderson T, Anderson G, Dasen S, et al. Pharmacokinetics and pharma-
codynamics of oral omeprazole in infants J Pediatr Gastroenterol Nutr
2001;33:416–25.
5. Omari T, Davidson G, Bondarov P, et al. Pharmacokinetics and acid-
suppressive effects of esomeprazole in infants 1-24 months old with
symptoms of gatroesophageal reflux disease. J Pediatr Gatroenterol Nutr
2007;45:530–7.
6. Tammara BK, Sullivan JE, Adcock KG, et al. Randomized, open-label,
multicenter pharmacokinetic studies of two dose levels of pantoprazole
granules in infants and children aged 1 month through <6 years with
gastro-oesophageal reflux disease. Clin Pharmacokinet 2011;50:541–50.
7. Buckley RH. T Lymphocytes, B lymphocytes, and natural killer cells. In:
Kliegman RM, Jenson HL, Behrman RE, Stanton BF (eds). Nelson
Textbook of Pediatrics. 18th ed.Philadelphia, PA: Saunders Elsevier;
2007. pp. 873–9.
8. Gunasekaran T, Hassall E. Efficacy and safety of omeprazole for severe
gastroesophageal reflux in children. J Pediatr 1993;123:148–54.
The Case for Thoughtful Prescribing of
Proton Pump Inhibitors in Infants
R eply: We appreciate the comments discussed in the letter byDrs Gunasekaran, Kakodkar, and Berman. Although the
authors lay out the case for the differential pharmacokinetics of
proton pump inhibitors in infants as a reason for cautious prescrib-
ing, we wanted to highlight that the main reason not to prescribe
these medications in infants is because they are not efficacious in
treating symptoms in otherwise healthy infants. Despite the fact that
between 23% and 71% of infants are prescribed either an H2
antagonist or a proton pump inhibitor worldwide, there are multiple
studies including placebo-controlled trials showing a lack of benefit
of acid suppression in improving symptoms of fussing, crying,
arching, apnea, cough, hoarseness, wheezing, or feeding intolerance
(1–4). The lack of efficacy may be multifactorial; symptoms may
not be reflux related or the reflux is a result of nonacidic gastric
contents getting refluxed (ie, formula or breast milk) upon which
acid suppression has no effect. So, although consideration of
pharmacokinetics and side effects are important when prescribing,
the biggest deterrent should be that these medications have con-
sistently been shown not to improve symptoms.
There are 2 notable populations in whom acid suppression
is warranted, those patients at high risk for esophagitis and those
with confirmed histologic esophagitis with eosinophilic infiltrates.
Children with esophageal motility disorders such as treated achalasia
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or esophageal atresia fall into this first category; any reflux that enters
the esophagus is poorly cleared because of profound disturbances of
peristalsis. Recognizing the impact of dysmotility on poor reflux
clearance is critical and, this population, we feel, merits aggressive
acid suppression therapy with proton pump inhibitors to prevent long-
term reflux complications including erosive esophagitis, metaplasia
of esophageal epithelium, and stricturing (5). Apart from patients
with dysmotility, a second population meriting therapy includes
symptomatic infants with eosinophilic infiltration of the esophagus
in whom proton pump inhibitor (PPI) therapy may help to narrow the
differential diagnosis including eosinophilic esophagitis, proton
pump inhibitor responsive eosinophilic esophagitis, and reflux eso-
phagitis.
As with all medications, prescribing needs to be done
thoughtfully and the pathophysiology of the signs and symptoms
needs to be considered. We whole heartedly agree that there is a
limited role for proton pump inhibitors in infants. Those infants with
motility disorders and confirmed esophagitis do, however, merit
therapy. Again, we assert that once prescribed, the benefit/risk ratio
of long-term PPI treatment should be balanced, and the need of
prolonged use of PPIs should be reassessed on a regular basis.
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